Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis
Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis
复制标题
DOI：
10.1371/journal.pntd.0004358
复制
发表时间：
2016-01-01
影响因子：
3.8
通讯作者：
Deming, Michael
中科院分区：
文献类型：
--
作者：
Budge, Philip J.;Sognikin, Edmond;Deming, Michael
背景实现大规模药物管理（MDA）的目标覆盖水平对于消除和控制几种被忽视的热带病（NTD）的努力至关重要。为确保达到计划目标，药品经销商报告的覆盖率可通过依赖于受访者回忆的家庭覆盖率调查进行验证。这是第一次研究，以评估准确性，在这样的surveillance.Methodology/Principal FindingsRecall准确性进行了测试，在一系列的覆盖率调查进行了1，6，12个月后，在多哥的综合MDA，在此期间，三种药物（阿苯达唑，伊维菌素，吡喹酮）进行了分配。在MDA期间观察药物分布，以确保准确记录MDA期间接受治疗的人员。分别在1个月、6个月和12个月时，对506人、1131人和947人进行了调查。根据治疗登记，这些群体的覆盖率（定义为至少服用一种MDA药物的人的百分比）分别为88.3%、87.4%和80.0%;根据调查答复，分别为87.9%、91.4%和89.4%。在1个月时，受访者和登记者之间关于吞咽至少一片药丸的一致性> 95%，在12个月时> 86%; 12个月时较低的一致性更可能是由于难以将调查受访者与一年前的治疗登记匹配，而不是不准确的回答。受访者一般区分药丸相似的外观;一致性召回的药丸被采取的是超过80%in each survey.SignificanceIn this population，覆盖率调查提供了显着一致的覆盖率估计为一年后的综合MDA。目前尚不清楚在其他环境中是否会看到类似的一致性，但是，这些数据表明，在某些环境中，覆盖率调查可能在MDA之后长达一年的时间内进行，而不会影响结果。这可能使MDA后的覆盖面测量纳入大型，多用途，定期调查，从而节省资源。
BackgroundAchieving target coverage levels for mass drug administration (MDA) is essential to elimination and control efforts for several neglected tropical diseases (NTD). To ensure program goals are met, coverage reported by drug distributors may be validated through household coverage surveys that rely on respondent recall. This is the first study to assess accuracy in such surveys.Methodology/Principal FindingsRecall accuracy was tested in a series of coverage surveys conducted at 1, 6, and 12 months after an integrated MDA in Togo during which three drugs (albendazole, ivermectin, and praziquantel) were distributed. Drug distribution was observed during the MDA to ensure accurate recording of persons treated during the MDA. Information was obtained for 506, 1131, and 947 persons surveyed at 1, 6, and 12 months, respectively. Coverage (defined as the percentage of persons taking at least one of the MDA medications) within these groups was respectively 88.3%, 87.4%, and 80.0%, according to the treatment registers; it was 87.9%, 91.4% and 89.4%, according to survey responses. Concordance between respondents and registers on swallowing at least one pill was > 95% at 1 month and > 86% at 12 months; the lower concordance at 12 months was more likely due to difficulty matching survey respondents with the year-old treatment register rather than inaccurate responses. Respondents generally distinguished between pills similar in appearance; concordance for recall of which pills were taken was over 80% in each survey.SignificanceIn this population, coverage surveys provided remarkably consistent coverage estimates for up to one year following an integrated MDA. It is not clear if similar consistency will be seen in other settings, however, these data suggest that in some settings coverage surveys might be conducted as much as one year following an MDA without compromising results. This might enable integration of post-MDA coverage measurement into large, multipurpose, periodic surveys, thereby conserving resources.